Regulatory Lilly plans Q1 2027 filing for obesity triple retatrutide PharmaphorumArmed with new pivotal trial results, Eli Lilly is preparing to file for approval of its triple-acting weight-loss therapy, retatrutide, next year.Metabolic & GLP-1Read full story pharminent July 23, 2026 (Last updated: July 23, 2026) Pharmaphorum Armed with new pivotal trial results, Eli Lilly is preparing to file for approval of its triple-acting weight-loss therapy, retatrutide, next year. Metabolic & GLP-1 Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: GSK’s $10.6B Nuvalent bet pays off early as FDA approves lung cancer drugNext: Lilly’s Retatrutide Hits 22.6% Weight Loss in Phase 3, But Cardiovascular Benefit Remains Elusive Related Stories Regulatory Replimune rebounds to win FDA approval of melanoma drug pharminent August 6, 2026 Regulatory Takeda’s first-in-class narcolepsy drug claims FDA approval pharminent August 6, 2026 Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026
